Author

Victor Cervera

Observed name: V.Z. Cervera

Institution: University of Helsinki

Observed institutions: University of Helsinki, Universidade de São Paulo

OpenAlex ID: A5108924817

Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.

2025 · Lyna Haybout, James Clubb, et al. · Journal of Clinical Oncology · 2

PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.

2024 · Joao Manuel Santos, Matthew Stephen Block, et al. · Journal of Clinical Oncology · 2

Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes.

2024 · Dafne Carolina Alves Quixabeira, Elise Jirovec, et al. · Journal of Clinical Oncology · 1

Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.

2025 · Victor Cervera, James Clubb, et al. · Journal of Clinical Oncology

Safety And Immunological Activity Of A Oncolytic Adenovirus Expressing TNFa And IL-2 In Combination With Pembrolizumab In Platinum-Resistant Or Refractory Ovarian Cancer Patients

2025 · Dafne C.A. Quixabeira, Matthew Block, et al. · International Journal of Gynecological Cancer

Aerobic Training Versus Behavioral Intervention to Increase Physical Activity in Patients With Asthma: A Preliminary Data From a Randomized Clinical Trial

2024 · D.H. Araujo Pinheiro, F.F. De Lima, et al. · American Journal of Respiratory and Critical Care Medicine

Works count: 6

Citation count: 5

H-index: 2

I10-index: